1-benzyl-3-(5-methoxymethyl-furan-2-yl)-1H-indazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-benzyl-3-(5-methoxymethyl-furan-2-yl)-1H-indazole
• 英文别名: 1-benzyl-3-(5'-methoxymethyl-2'-furyl)indazole；1-benzyl-3-(5'-methoxymethyl)furyl-indazole；1-benzyl-3-[5-(methoxymethyl)furan-2-yl]indazole
• 化学式: C₂₀H₁₈N₂O₂
• 分子量: 318.375
• InChiKey: DQMKVEMOQGAQPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  40.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-苯甲酰基呋喃-2-甲酸甲酯 在 lead(IV) acetate 、 calcium borohydride 、 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 8.5h， 生成 1-benzyl-3-(5-methoxymethyl-furan-2-yl)-1H-indazole
  参考文献：
  名称：

  1-Benzyl-3-(5‘-hydroxymethyl-2‘-furyl)indazole (YC-1) Derivatives as Novel Inhibitors Against Sodium Nitroprusside-Induced Apoptosis

  摘要：

  Antiapoptotic agents based on 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (22, YC-1) derivatives were explored for effective treatment of sepsis and septic shock. We found that compound 22, 1-benzyl-3-(5'-methoxymethyl-2'-furyl)indazole (27), and 1-phenyl-3-(5'-hydroxymethyl-2'-furyl)-indazole (23) were the most effective inhibitors of sodium nitroprusside-induced vascular smooth muscle cell apoptosis. These three compounds are proposed as potential therapeutic agents for the treatment of sepsis.

  DOI：

  10.1021/jm020070b

文献信息

• Method of treating disorders related to protease-activated receptors-induced cell activation
  申请人：——

  公开号：US20020004518A1

  公开（公告）日：2002-01-10

  A method of treating a disorder related to cell activation induced by protease-activated receptors. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl group, via an via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.

  一种治疗与蛋白酶激活受体引起的细胞活化相关障碍的方法。该方法包括向需要的受试者施用具有吡唑基核的化合物；通过烷基连接剂与吡唑基核的1-N键合的芳基团；在吡唑基核的4-C和5-C处融合的第二个芳基团；以及直接与吡唑基核的3-C键合的第三个芳基团。
• Novel fused pyrazolyl compounds having an aminoalkylcarbonyl group
  申请人：Kuo Sheng-Chu

  公开号：US20090131681A1

  公开（公告）日：2009-05-21

  A fused pyrazolyl compound having an anti-tumor potency of the following formula is synthesized: wherein A is in which n is 0, 1, 2, or 3; Ar 1 is benzene, thiophene or furan; Ar 2 is furyl; and Ar 3 is phenyl; R 1 and R 2 independently are hydrogen, halogen or —(CH 2 ) m OR e ; R 3 is hydrogen or alkyl; R 4 is —(CH 2 ) r -A 1 , wherein r is an integer of 1-5, and A 1 has a formula of —O—C(O)—(CR c H) q —NR c′ R d′ ; R 5 and R 6 independently are hydrogen, halogen, or alkyl, or R 5 and R 6 together are —O(CH 2 ) m O—; R c is H, halogen, nitro, cyano, alkyl, or aryl; R e is H, alkyl, or aryl; R c′ and R d′ independently are H, alkyl, or aryl; m is 0, 1, 2, 3, 4, 5, or 6; and q is 1, 2, 3, 4, 5, or 6; or a salt thereof.

  已合成具有以下化学式的具有抗肿瘤活性的融合吡唑基化合物：其中A为，其中n为0、1、2或3；Ar1为苯、噻吩或呋喃；Ar2为呋喃基；Ar3为苯基；R1和R2独立地为氢、卤素或—(CH2)mORe；R3为氢或烷基；R4为—(CH2)r-A1，其中r为1-5的整数，A1具有—O—C(O)—(CRcH)q—NRc′Rd′的化学式；R5和R6独立地为氢、卤素或烷基，或者R5和R6一起为—O(CH2)mO—；Rc为H、卤素、硝基、氰基、烷基或芳基；Re为H、烷基或芳基；Rc′和Rd′独立地为H、烷基或芳基；m为0、1、2、3、4、5或6；q为1、2、3、4、5或6；或其盐。
• Treatment of disorder related to low cyclic GMP levels
  申请人：——

  公开号：US20030220385A1

  公开（公告）日：2003-11-27

  Methods of treating a disorder associated with low cGMP levels. The methods include administering to a subject in need thereof an effective amount of a compound having a pyrazolyl core, a first aryl group bonded to 3-C of the pyrazolyl core, and a second aryl group fused at 4-C and 5-C of the pyrazolyl core. Also disclosed are pharmaceutical compositions containing these compounds.

  治疗与低cGMP水平相关的疾病的方法。该方法包括向需要的受试者施用具有吡唑基核、第一芳基基团与吡唑基核的3-C键合，以及第二芳基基团融合在吡唑基核的4-C和5-C处的化合物的有效量。还公开了含有这些化合物的制药组合物。
• Compounds, compositions and methods
  申请人：Park Jong-Wan

  公开号：US20050187276A1

  公开（公告）日：2005-08-25

  The present invention provides methods and pharmaceutical compositions for inhibiting expressions of HIF and HIF regulated genes, inhibiting angiogenesis, inducing cell cycle arrest in tumor cells, and treating cell proliferating diseases or conditions.

  本发明提供了一种抑制HIF和HIF调节基因表达、抑制血管生成、诱导肿瘤细胞细胞周期停滞和治疗细胞增殖性疾病或情况的方法和制药组合物。
• Treatment of nuerodegenerative diseases
  申请人：——

  公开号：US20040077702A1

  公开（公告）日：2004-04-22

  This invention features a method for treating a neurodegenerative disease. The method includes administrating to a subject in need thereof a compound of the formula (I): 1 A is H, R, or 2 each of Ar 1 , Ar 2 , and Ar 3 , independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 , independently, is H, halogen, R, C(O)OH, C(O)OR, C(O)SH, C(O)SR, C(O)NH 2 , C(O)NHR, C(O)NRR′, ROH, ROR′, RSH, RSR′, NHR, NRR′, RNHR′, or RNR′R″; or R 1 and R 2 together, R 3 and R 4 together, or R 5 and R 6 together are ORO; wherein each of R, R′, and R″, independently is C 1 ˜C 6 alkyl; and n is 1, 2, or 3.

  这项发明涉及一种治疗神经退行性疾病的方法。该方法包括向需要治疗的受体中注射化合物(I)的化合物：1A为H，R或2；每个Ar1、Ar2和Ar3独立地为苯基、噻吩基、呋喃基或吡咯基；每个R1、R2、R3、R4、R5和R6独立地为H、卤素、R、C（O）OH、C（O）OR、C（O）SH、C（O）SR、C（O）NH2、C（O）NHR、C（O）NRR′、ROH、ROR′、RSH、RSR′、NHR、NRR′、RNHR′或RNR′R″；或R1和R2结合，R3和R4结合，或R5和R6结合为ORO；其中每个R、R′和R″独立地为C1˜C6烷基；n为1、2或3。